Form 4: Century Therapeutics Director Granted Stock Options

Century Therapeutics, Inc. reports the grant of stock options to Director Martin Patrick Murphy.

Summary

• Martin Patrick Murphy, a Director at Century Therapeutics, Inc., was granted 88,000 stock options on December 9, 2025.
• These options have an exercise price of $0.592 and are exercisable until December 9, 2035.
• The options vest in equal monthly installments over 36 months, contingent on continued service.
• The grant is part of the Company's 2021 Equity Incentive Plan.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard compensation grant to a director rather than a significant financial event.

Positives

• Director Martin Patrick Murphy has been granted a significant number of stock options (88,000), aligning his interests with the company's performance.
• The stock options vest over 36 months, incentivizing long-term commitment from the director.
• The grant is made under the company's established 2021 Equity Incentive Plan, indicating a structured approach to compensation.

Risks

• The value of the stock options is directly tied to the future performance of Century Therapeutics, Inc. stock.
• Vesting is contingent on continued service, meaning the director could forfeit unvested options if service is terminated.

Future Outlook

The future outlook for the stock options is dependent on the company's stock performance and the director's continued service over the next 36 months.

Industry Context

StockSavvy.ai notes that granting stock options to directors is a common practice in the biotechnology and pharmaceutical sectors to attract and retain talent and align executive interests with shareholder value.

Management Changes

Stakeholder Impact

• Shareholders: The grant of options aligns director interests with shareholder value, potentially leading to decisions that benefit the company's stock price.
• Employees: The existence of an equity incentive plan suggests a broader compensation strategy that may include employee participation in future grants.
• Management: The compensation structure for directors is clearly defined, contributing to transparent corporate governance.

Next Steps

• The director will continue to serve the company, and the stock options will vest over the next 36 months.
• The company will continue to operate under its 2021 Equity Incentive Plan.

Key Dates

Keywords

Century Therapeutics, IPSC, Form 4, Stock Options, Director Compensation, Equity Incentive Plan, Beneficial Ownership